- Datum02.04.2025
- Uhrzeit15:00 - 16:00 Uhr
- Veranstalter
XTB
Jochen Schmidt
Moderator
Janux Therapeutics Aktie
Verkaufen
Kaufen
Janux Therapeutics Chart
Janux Therapeutics Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Freestoxx | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,65 %
Intraday
-10,99 %
1 Woche
-18,49 %
1 Monat
-49,93 %
Seit Jahresbeginn
-25,26 %
1 Jahr
76,85 %
3 Jahre
Wikifolio
Passender Service zu Janux Therapeutics
Webinar zu Janux Therapeutics
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)26,390-71,710
- Jahrestief / Hoch ($)26,390-61,590
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Janux Therapeutics
Keine Dividenden verfügbar
Termine von Janux Therapeutics
Keine aktuellen Termine
Beschreibung
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
